bearish
Obi Pharma Inc (4174 TT): Inherent Pipeline Risk Has Clouded Near-Term Outlook
459 Views20 Jan 2023 23:22
SUMMARY
- Obi Pharma Inc (4174 TT) is developing novel therapeutic agents for unmet medical needs against cancers. The company’s lead pipeline candidate, adagloxad simolenin is a first-in-class cancer vaccine candidate.
- Currently, adagloxad simolenin is in phase 3 study as an adjuvant treatment of high-risk, early-stage, Globo H-positive triple negative breast cancer, which represents 15–20% of breast cancer cases.
- The company has a cash runway through 2024, while phase 3 trial is expected to be completed in 2025. With the pipeline progress, operating expenses are expected to increase.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
x